This is one of those situations that’s likely to get more and more common, I guess, as treatments that prolong life, rather than cure cancer, get developed, but with a potential for major cost implications. Now, we’ve had concerns, which you know well about, about IPFR and exceptionality, and I certainly look forward to seeing how changes recently announced will improve access. But we’re also concerned about whether the current appraisal processes reflect the changing way that medicines are developed and used in clinical practice. Do you think that the current system is sustainable, or will public concerns—whether those concerns are justified or not—lead to you making changes, do you think?